17h agoThe FlyBEARISH 36Earnings
Archived explainer. For the current picture see today's VKTX page.
Why Is VIKING THERAPEUTICS (VKTX) Stock Down Today?
By the Top Tier Newswire AI Desk · September 25, 2026 at 12:23 AM ET · reviewed against 27 wire stories
VIKING THERAPEUTICS (VKTX) is down -11.76% in the latest session. Our newswire has captured 27 stories on VKTX across 13 sources in the last 36 hours, with AI sentiment reading bearish (avg 37/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why VKTX stock is down today
Viking Therapeutics shares fell 11.76% to $36.75 in a single session, driven by the company's announcement of a $500 million capital-raising effort. The stock price decline reflects investor reaction to the dilutive nature of the offering, which includes the sale of 7.86 million new shares at $35 each and the issuance of $200 million in convertible senior notes. The offering priced at a 16% discount to the stock's closing price on Wednesday, signaling a potential selloff.
The company disclosed plans for two separate public offerings: $200 million of common stock and $200 million of convertible senior notes due 2032, with a 30-day option for up to $30 million in additional funding. The concurrent offering features 2% notes that convert initially at $50.75 per share. Base net proceeds of $476.2 million nearly match the company’s liquidity as of June. The move is expected to nearly double Viking’s cash runway, but the immediate price reaction has been negative.
What The Data Shows
The stock had previously gained 20.1% over the last eight sessions, rising from $29.95 to $35.97. However, the recent offering has triggered a sharp reversal. The company’s fundamentals remain weak, with an unprofitable status (EPS TTM -4.67) and a beta of 0.68. The offering has also coincided with recent insider sales, including transactions by COO Marianna Mancini, CEO Brian Lian, and CFO Greg Zante, who collectively sold $6.3 million in shares over the last 90 days. Additionally, the stock printed one fresh 52-week low on September 24, 2026, while 15 stocks hit 52-week highs on the same day. Unusual options activity has also been observed, with $1.5 million in call premiums and no put premiums traded.
What To Watch
Viking Therapeutics has not disclosed an upcoming earnings date. Investors should monitor the breadth of coverage and sentiment shifts in the coming days, as well as any follow-up developments on the financing deal and its impact on the company’s operations.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
VKTX by the numbers
Last: $36.75Session: -11.76%7 sessions: +20.10%Coverage: 27 stories / 13 sourcesAI sentiment: 37/100 (bearish)Mkt cap: $3.5B52w: $24.78 to $43.15
The headlines behind the move
18h agoMarketChameleonBEARISH 24General
Viking Therapeutics Plans $200 Million Stock Deal and $200 Million Convertible Notes to Fund VK2735 and VK3019 September 24, 2026
Viking Therapeutics announced plans for two separate public offerings: $200.0 million of common stock and $200.0 million of convertible senior notes due 2032, each with a 30-day option for up to $30.0 million in additional securities. The company said proceeds are intended to support continued development and advancement of VK2735 and VK3019, alongside other R&D and corporate purposes, while final terms and completion remain subject to market conditions.
18h agoThe Motley FoolBEARISH 42General
Here's Why Viking Therapeutics Shares Slumped Today
It's been an eventful week for the weight-loss drug company, which continues to impress with its clinical data, and today's move isn't much to worry about.
19h ago24/7 Wall St.BEARISH 28General
Viking Therapeutics Sinks 15% After Pricing Upsized $500M Offering; Jaguar Health Tumbles 25%
Two biotech names are moving sharply lower Thursday morning while the sector benchmark grinds higher, a split move that puts the day’s action on the companies themselves rather than on any broader rotation. Viking Therapeutics (NASDAQ:VKTX) is under pressure after pricing an upsized financing before the open, and Jaguar Health, Inc. (NASDAQ:JAGX) is sliding harder […]
19h agoTechStock²BEARISH 24General
Viking Therapeutics Stock Drops After $500 Million Deal; Cash Runway Nearly Doubles
San Diego, September 24, 2026, 07:10 (PDT) Viking priced 7.86 million new shares at $35 each.The concurrent 2% notes convert initially at $50.75 per share.Base net proceeds of $476.2 million nearly match June liquidity. Viking Therapeutics, Inc. (NASDAQ:VKTX) shares fell 13.6% to $35.99 at 10:05 EDT Thursday. The drop followed a $500 million stock-and-convertible offering…
19h agoThe FlyBEARISH 37Earnings
Viking Therapeutics falls -13.1%
20h agoStocktwits NewsBEARISH 28General
VKTX Stock Heads Toward Worst Day In Over A Year Just Days After Promising Weight Loss Drug Data — Here’s What’s Driving The Selloff
Viking Therapeutics priced an upsized financing deal at a 16% discount from the stock’s closing price on Wednesday.
21h agoInvesting.com MarketsBEARISH 32General
Why is Viking Therapeutics stock tumbling today?
Why is Viking Therapeutics stock tumbling today?
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on VKTX: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier VKTX move explainers: 2026-09-25 · 2026-09-24 · 2026-09-23 · 2026-09-22 · 2026-08-31